No new safety concerns found in Ofev, study reveals

13 November 2015

Post-marketing surveillance of the efficacy and safety of Ofev (nintedanib) – which is used to treat idiopathic pulmonary fibrosis (IPF) – has identified no new safety concerns.

Ofev, manufactured by German family-owned drug maker Boehringer Ingelheim, was approved by the US Food and Drug Administration on October 15, 2014 and by the European Medicines Agency at the start of this year.

The latest data, presented at the Pulmonary Fibrosis Foundation’s (PFF) Summit 2015 in Washington, reveals a safety profile consistent with the clinical studies supporting FDA approval of Ofev.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK